Targeting the androgen receptor-theory and practice

Urology

Volumn 78, Issue 5 SUPPL., 2011, Pages

  Dreicer, Robert ^a,b   Gleave, Martin ^c   Kibel, Adam S ^d   Thrasher, J Brantley ^e   Moul, Judd W ^f  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; DOCETAXEL; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; MESSENGER RNA; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NONHUMAN; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; TESTOSTERONE BLOOD LEVEL;

ANDROGEN RECEPTOR ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 80755172344     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.052     Document Type: Article

References (21)

1. C. Huggins, and C.V. Hodges Studies on prostatic cancer I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. H. Akaza Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness Cancer Sci 102 2011 51 56
3. K.E. Knudsen, and H.I. Scher Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clin Cancer Res 15 2009 4792 4798
4. H.I. Scher, and C.K. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 2005 8253 8261 (Pubitemid 46211563)
5. J.P. Moreau, P. Delavault, and J. Blumberg Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy Clin Ther 28 2006 1485 1508 (Pubitemid 44841984)
6. G. Emons, and A.V. Schally The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers Hum Reprod 9 1994 1364 1379 (Pubitemid 24224014)
7. R.B. Montgomery, E.A. Mostaghel, and R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
8. C.D. Chen, D.S. Welsbie, and C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39 (Pubitemid 38524696)
9. J.A. Locke, E.S. Guns, and A.A. Lubik Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 69 2008 6407 6415
10. C.D. Taylor, P. Elson, and D.L. Trump Importance of continued testicular suppression in hormone-refractory prostate cancer J Clin Oncol 11 1993 2167 2172 (Pubitemid 23332253)
11. M. Hussain, M. Wolf, and E. Marshall Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report J Clin Oncol 12 1994 1868 1875
12. H.I. Scher, and G. Heller Clinical states in prostate cancer: toward a dynamic model of disease progression Urology 55 2000 323 327 (Pubitemid 30110575)
13. M.R. Cooperberg, G.D. Grossfeld, and D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989 (Pubitemid 36896715)
14. M.R. Smith, F. Kabbinavar, and F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925 (Pubitemid 46224110)
15. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726 729 (Pubitemid 30637611)
16. W. Rosner, H. Vesper Endocrine Society, American Association for Clinical Chemistry, American Association of Clinical Endocrinologists, Androgen Excess/PCOS Society, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Urological Association, Association of Public Health Laboratories, Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society Toward excellence in testosterone testing: a consensus statement J Clin Endocrinol Metab 95 2010 4542 4548
17. M.G. Oefelein, A. Feng, and M.J. Scolieri Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
18. J. Morote, A. Orsola, and J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 4 Pt. 1 2007 1290 1295 (Pubitemid 47368393)
19. G. Attard, A.H.M. Reid, and T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
20. R. Dreicer, D.B. Agus, and G.R. MacVicar Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study (abstract) J Clin Oncol 28 2010 15s
21. J. de Bono, C. Logothetis, and K. Fizazi Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study Ann Oncol 21 suppl 8 2010 LBA5